SLC16A1 and neoplasm: Monocarboxylate transporter 1 (MCT-1) inhibition, which restricted uptake of ketone bodies and lactate, or treatment with mitoketoscins, which disrupted mitochondrial function, led to tumor shrinkage and a loss of stemness [45,46].